CN103721103B - 用于治疗猪丹毒的药物及其制备方法 - Google Patents
用于治疗猪丹毒的药物及其制备方法 Download PDFInfo
- Publication number
- CN103721103B CN103721103B CN201310744844.2A CN201310744844A CN103721103B CN 103721103 B CN103721103 B CN 103721103B CN 201310744844 A CN201310744844 A CN 201310744844A CN 103721103 B CN103721103 B CN 103721103B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- semen
- medicine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 109
- 201000000297 Erysipelas Diseases 0.000 title claims abstract description 44
- 238000011282 treatment Methods 0.000 title claims abstract description 30
- 229940079593 drug Drugs 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 10
- 210000000582 semen Anatomy 0.000 claims abstract description 88
- 241000628997 Flos Species 0.000 claims abstract description 26
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 17
- 241001251068 Formica fusca Species 0.000 claims abstract description 16
- 240000007594 Oryza sativa Species 0.000 claims abstract description 16
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 16
- 239000000454 talc Substances 0.000 claims abstract description 16
- 235000012222 talc Nutrition 0.000 claims abstract description 16
- 229910052623 talc Inorganic materials 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- 239000002023 wood Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 241000411859 Burmannia coelestis Species 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 35
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 241000282898 Sus scrofa Species 0.000 description 50
- 239000008280 blood Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 33
- 210000000952 spleen Anatomy 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 210000004072 lung Anatomy 0.000 description 27
- 201000010099 disease Diseases 0.000 description 25
- 210000002784 stomach Anatomy 0.000 description 24
- 206010011224 Cough Diseases 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 231100000614 poison Toxicity 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 210000001015 abdomen Anatomy 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 14
- 239000003440 toxic substance Substances 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 206010007247 Carbuncle Diseases 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 208000001848 dysentery Diseases 0.000 description 10
- 230000001047 pyretic effect Effects 0.000 description 10
- 206010037844 rash Diseases 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 9
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 9
- 208000010201 Exanthema Diseases 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 201000005884 exanthem Diseases 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 241000193830 Bacillus <bacterium> Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 8
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 208000002474 Tinea Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 241000130764 Tinea Species 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 5
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 206010014665 endocarditis Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010041660 Splenomegaly Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- -1 analgesia Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 210000003026 hypopharynx Anatomy 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010020741 Hyperpyrexia Diseases 0.000 description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 206010043458 Thirst Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 229960003022 amoxicillin Drugs 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 231100000429 cutaneous necrosis Toxicity 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000010685 fatty oil Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 241000405911 Rehmannia glutinosa Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 241000245665 Taraxacum Species 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241001093951 Ailanthus altissima Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000008710 Amebic Dysentery Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010970 Cor pulmonale chronic Diseases 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241001535083 Dialister Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 101150076104 EAT2 gene Proteins 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019340 Heat oedema Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000024949 Swine Erysipelas Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000008578 acute process Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000010424 alunite Substances 0.000 description 1
- 229910052934 alunite Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004467 ceftiofur sodium Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 208000026636 chronic pulmonary heart disease Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000008570 maxingshigan Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002960 penicillins Chemical group 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004341 tarsal joint Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- KPZTWMNLAFDTGF-UHFFFAOYSA-D trialuminum;potassium;hexahydroxide;disulfate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KPZTWMNLAFDTGF-UHFFFAOYSA-D 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗猪丹毒的药物,由以下原料药组成:金银花、麻腐、南酸枣、天花粉、大蒜、马铃薯、蚂蚁、达仑木、大黄、糯米、滑石、射干、山豆根、大青叶、葶苈子、丹皮、生地黄、玄参、甘草、杏仁、地丁、柳絮、浮萍、白矾和蒲公英。本发明的有益效果是:本发明采用中药组合物对猪丹毒预防具有疗效显著,副作用低,治愈率高、疗程短、不易复发等优点。
Description
技术领域
本发明涉及中兽药技术领域,特别涉及一种用于治疗猪丹毒的药物及其制备方法。
背景技术
猪丹毒是猪丹毒杆菌引起的一种急性热性传染病,其主要特征为高热、急性败血症、皮肤疹块(亚急性)、慢性疣状心内膜炎及皮肤坏死与多发性非化脓性关节炎(慢性)。目前集约化养猪场比较少见,但仍未完全控制。本病呈世界性分布。猪丹毒杆菌是一种革兰氏阳性菌,具有明显的形成长丝的倾向。本菌为平直或微弯纤细小杆菌,大小为0.2~0.4微米×0.8~2.5微米。在病料内的细菌,单在、成对或成丛排列,在白细胞内一般成丛存在,在陈旧的肉汤培养物内和慢性病猪的心内膜疣状物中,多呈长丝状,有时很细。本菌对盐腌、火熏、干燥、腐败和日光等自然环境的抵抗力较强。
在病死猪的肝、脾内4℃159天,毒力仍然强大。露天放置27天的病死猪肝脏,深埋1.5米231天的病猪尸体,12.5%食盐处理并冷藏于4℃148天的猪肉中,都可以分离到猪丹毒杆菌。在一般消毒药,如2%福尔马林、l%漂白粉、1%氢氧化钠或5%碳酸中很快死亡。对热的抵抗力较弱,肉汤培养物于50℃经12~20分钟,70℃5分钟即可杀死。本菌的耐酸性较强,猪胃内的酸度不能杀死它,因此可经胃而进入肠道。
猪丹毒的病理变化为:(1)急性型胃底及幽门部勃膜发生弥漫性出血,小点出血;整个肠道都有不同程度的卡他性或出血性炎症;脾肿大,呈典型的败血脾;肾淤血、肿大,有“大紫肾”之称;淋巴结充血、肿大,切面外翻,多汁,肺脏淤血、水肿(2)亚急性型充血斑中心可因水肿压迫呈苍白色。(3)慢性型①心内膜炎:在心脏可见到疵状心内膜炎的病变二尖瓣和主动脉瓣出现菜花样增生物。②关节炎:关节肿胀,有浆液性、纤维素性渗出物蓄积。
猪丹毒的主要症状为:临床症状潜伏期短的1天,长的7天。急性型:此型常见,以突然爆发、急性经过和高死亡为特征。病猪精神不振、高烧不退;不食、呕吐;结膜充血;粪便干硬,附有粘液。小猪后期下痢。耳、颈、背皮肤潮红、发紫。临死前腋下、股内、腹内有不规则鲜红色斑块,指压褪色后而融合一起。常于3-4天内死亡。病死率80%左右,不死者转为疹块型或慢性型。哺乳仔猪和刚断乳的小猪发生猪丹毒时,一般突然发病,表现神经症状,抽搐,倒地而死,病程多不超过一天。亚急性型(疹块型):病较轻,头一两天在身体不同部位,尤其胸侧、背部、颈部至全身出现界限明显,圆形、四边形,有热感的疹块,俗称“打火印”,指压退色。疹块突出皮肤2-3毫米,大小约一至数厘米,从几个到几十个不等,干枯后形成棕色痂皮。病猪口渴、便秘、呕吐、体温高。疹块发生后,体温开始下降,病势减轻,经数日以至旬余,病猪自行康复。也有不少病猪在发病过程中,症状恶化而转变为败血型而死。病程约1-2周。慢性型:由急性型或亚急性型转变而来,也有原发性,常见的有慢性关节炎、慢性心内膜炎和皮肤坏死等几种。慢性关节炎型主要表现为四肢关节(腕、跗关节较膝、髋关节最为常见)的炎性肿胀,病腿僵硬、疼痛。以后急性症状消失,而以关节变形为主,呈现一肢或两肢的破行或卧地不起。病猪食欲正常,但生长缓慢,体质虚弱,消瘦。病程数周或数月。慢性心内膜炎型主要表现消瘦,贫血,全身衰弱,喜卧,厌走动,强使行走,则举止缓慢,全身摇晃。听诊心脏有杂音,心跳加速、亢进,心律不齐,呼吸急促。此种病猪不能治愈,通常由于心脏麻痹突然倒地死亡。溃疡性或椰菜样疣状赘生性心内膜炎。心律不齐、呼吸困难、贫血。病程数周至数月。慢性型的猪丹毒有时形成皮肤坏死。常发生于背、肩、耳、蹄和尾等部。局部皮肤肿胀、隆起、坏死、色黑、干硬、似皮革。逐渐与其下层新生组织分离,犹如一层甲壳。坏死区有时范围很大,可以占整个背部皮肤;有时可在部分耳壳、尾巴、末梢、各蹄壳发生坏死。约经2~3个月坏死皮肤脱落,遗留一片无毛、色淡的疤痕而愈。如有继发感染,则病情复杂,病程延长。
目前预防和治疗猪丹毒药物为青霉素类(阿莫西林)、头孢类(头孢噻呋钠)。但是西药的副作用比较大,而且西药在治疗时只对单一的病症或者一类病症有明显的疗效,对于一些病症较多的疾病,疗效不太明显,常常需要开很多的西药,价格较高;很多中药在治疗猪丹毒时主要从抗菌、抗炎、清热解毒,活血消斑等多方面对机体进行调节。与抗生素相比,中药非单纯的抗菌。中药多数来源于天然植物,其成分复杂,使细菌不易产生耐药性,也不易造成药物残留。近年来中药在治疗仔猪白痢方面的作用引起人们的广泛关注。
发明内容
本发明所要解决的技术问题是在于提供一种用于治疗猪丹毒的药物及其制备方法,采用这种药物对猪丹毒疾病的治疗具有疗效显著,副作用低,治愈率高,不易复发等优点。
为了实现上述发明目的,本发明提供了用于治疗猪丹毒的药物,所述药物由以下原料药组成:金银花、麻腐、南酸枣、天花粉、大蒜、马铃薯、蚂蚁、达仑木、大黄、糯米、滑石、射干、山豆根、大青叶、葶苈子、丹皮、生地黄、玄参、甘草、杏仁、地丁、柳絮、浮萍、白矾和蒲公英。
所述药物由以下重量份数的原料药组成:金银花10~20重量份、麻腐18~28重量份、南酸枣10~26重量份、天花粉10~20重量份、大蒜10~20重量份、马铃薯10~15重量份、蚂蚁10~20重量份、达仑木10~26重量份、大黄10~20重量份、糯米10~15重量份、滑石10~26重量份、射干10~25重量份、山豆根10~15重量份、大青叶10~20重量份、葶苈子10~20重量份、丹皮10~24重量份、生地黄10~26重量份、玄参10~20重量份、甘草10~24重量份、杏仁10~24重量份、地丁10~20重量份、柳絮10~20重量份、浮萍10~15重量份、白矾10~15重量份和蒲公英10~20重量份。
所述药物由以下重量份数的原料药组成:金银花12~17重量份、麻腐19~25重量份、南酸枣14~22重量份、天花粉13~18重量份、大蒜12~17重量份、马铃薯10~15重量份、蚂蚁15~20重量份、达仑木15~26重量份、大黄10~15重量份、糯米10~15重量份、滑石10~18重量份、射干10~21重量份、山豆根10~15重量份、大青叶10~17重量份、葶苈子10~16重量份、丹皮12~20重量份、生地黄13~18重量份、玄参13~18重量份、甘草13~21重量份、杏仁15~21重量份、地丁12~17重量份、柳絮12~18重量份、浮萍13~15重量份、白矾13~15重量份和蒲公英13~17重量份。
所述药物由以下重量份数的原料药组成:金银花15重量份、麻腐23重量份、南酸枣18重量份、天花粉15重量份、大蒜15重量份、马铃薯13重量份、蚂蚁17重量份、达仑木21重量份、大黄13重量份、糯米13重量份、滑石14重量份、射干15重量份、山豆根12重量份、大青叶15重量份、葶苈子13重量份、丹皮16重量份、生地黄15重量份、玄参16重量份、甘草17重量份、杏仁18重量份、地丁15重量份、柳絮15重量份、浮萍14重量份、白矾14重量份和蒲公英15重量份。
所述药物还包括以下原料药:陈皮、地沙、丁香和山楂。
所述药物优选的由以下原料药组成:金银花12~17重量份、麻腐19~25重量份、南酸枣14~22重量份、天花粉13~18重量份、大蒜12~17重量份、马铃薯10~15重量份、蚂蚁15~20重量份、达仑木15~26重量份、大黄10~15重量份、糯米10~15重量份、滑石10~18重量份、射干10~21重量份、山豆根10~15重量份、大青叶10~17重量份、葶苈子10~16重量份、丹皮12~20重量份、生地黄13~18重量份、玄参13~18重量份、甘草13~21重量份、杏仁15~21重量份、地丁12~17重量份、柳絮12~18重量份、浮萍13~15重量份、白矾13~15重量份、蒲公英13~17重量份、陈皮10~15重量份、地沙10~20重量份、丁香10~20重量份和山楂10~20重量份。
所述药物优选的由以下原料药组成:金银花15重量份、麻腐23重量份、南酸枣18重量份、天花粉15重量份、大蒜15重量份、马铃薯13重量份、蚂蚁17重量份、达仑木21重量份、大黄13重量份、糯米13重量份、滑石14重量份、射干15重量份、山豆根12重量份、大青叶15重量份、葶苈子13重量份、丹皮16重量份、生地黄15重量份、玄参16重量份、甘草17重量份、杏仁18重量份、地丁15重量份、柳絮15重量份、浮萍14重量份、白矾14重量份、蒲公英15重量份、陈皮13重量份、地沙15重量份、丁香15重量份和山楂15重量份。
为了更好的实现上述发明目的,本发明提供了一种用于治疗猪丹毒的药物的制备方法,所述制备方法包括以下步骤:
第一步,将所有原料药按比例混合,粉碎成粉末,装入多功能提取罐中,加入相对于混合物质量3~5倍的醇浓度为80%~90%的乙醇,加热回流1小时~3小时提取,获得提取液,加热回流过程中的蒸汽压力为0.4MPa~0.6MPa,将提取液过滤获得第一过滤液和滤渣;
第二步,将第一步获得的滤渣加入相对于第一步混合物质量1~3倍的醇浓度为80%~90%的乙醇,加热回流0.5小时~1.5小时提取,获得提取液,加热回流过程中的蒸汽压力为0.4MPa~0.6MPa,将提取液过滤获得第二过滤液;
第三步,将第一过滤液和第二过滤液合并,减压浓缩除去溶剂,获得干膏,将干膏放入喷雾干燥机中干燥,保证进风温度在170℃~190℃,出风温度60℃~80℃,随后粉碎成200目~400目,获得粉末药物。
本发明实施例提供的技术方案带来的有益效果是:本发明的药物以清热泻火、滋阴生津、理气理血、调理脾胃为主要治疗原则,对猪丹毒治疗具有疗效显著,副作用低,治愈率高、疗程短、不易复发等优点。
具体实施方式
中药主要是通过抗菌,提高机体免疫力,增强抗病能力,抗炎,减轻症状,保持胃肠道菌群平衡,抑制胃肠蠕动,改善机体血液理化指标等作用来治疗猪丹毒。按照中兽医学理论,猪丹毒的发病与多种因素有关,猪体质弱、气候变化,饮食问题等都可。中兽医学从气虚血热论之,营气虚而不能推动血行,故血热枉行而溢出经络出现淤血斑,或者由于热上伤津液,导致津液枯竭,金代医家刘完素认为:肾为水脏,虚则热,实则寒。心为火脏,靠肾水制约,故主张以养肾水泻心火的治疗法则。养肾水是治本,泻心火是治标。《素问·玄机原病式》:“泻实补虚,平而已矣。”猪丹毒主要使用清热泻火药,更重要的是重用滋阴生津药。气血不通,百病乃生,不通则痛,猪丹毒时营气虚弱,不能推动血行,热血枉行于经络之外,故产生出血斑疹。因此猪丹毒治疗理气理血,消斑透疹。通过促使气血运行,使机体内各种营养成分在体内逐渐向最佳配置。脾为后天之本,脾为脏中之母,脾胃如同树根,没有脾的生化作用,诸脏失去营养,生命无法存在,胃为纳谷之海,没有胃的作用,脾无法进行生化运化,所以还要注意调理脾胃。
依据上述原理,本发明以清热泻火、滋阴生津、理气理血、调理脾胃为主要治疗原则,提供了一种用于治疗猪丹毒的药物,其原料药包括:金银花、麻腐、南酸枣、天花粉、大蒜、马铃薯、蚂蚁、达仑木、大黄、糯米、滑石、射干、山豆根、大青叶、葶苈子、丹皮、生地黄、玄参、甘草、杏仁、地丁、柳絮、浮萍、白矾和蒲公英。
方中,各原料药的药理如下:
金银花:味甘、性寒,入心、肺、胃、大肠经,有清热解毒的作用,兼能凉血止痢,主要用于外感风热、温热病热毒较盛,或温病初起热邪尚在上焦而未下行时;热毒下痢、大便下血;暑温证;热毒积聚之疮痈初起,焮热肿痛者,以及其他皮肤感染,该物有较好的退热作用,有抗炎作用,能促进白细胞的吞噬功能,对多种化脓性球菌及肠道致病菌有较强的抑菌作用。
麻腐:利肠胃,解热毒,滋益精髓,最利老人。润肌,滑肠,解毒。
南酸枣:味甘;酸;性平。归脾;肝经。功能主治:行气活血;养心安神;消积;解毒。主气滞血瘀;胸痛;心悸气短;神经衰弱;失眠;支气管炎;食滞腹满;腹泻;疝气;烫火伤。
天花粉:甘、微苦,微寒。归肺、胃经。清热生津,消肿排脓。用于热病烦渴,肺热燥咳,内热消渴,疮疡肿毒。《纲目》:栝楼根,味甘微苦酸,酸能生津,故能止渴润枯,微苦降火,甘不伤胃,昔人只言其苦寒,似未深察。《本草汇言》:天花粉,退五脏郁热,如心火盛而舌干口燥,肺火盛而咽肿喉痹,脾火盛而口舌齿肿,痰火盛而咳嗽不宁。若肝火之胁胀走注,肾火之骨蒸烦热,或痈疽已溃未溃,而热毒不散,或五疸身目俱黄,而小水若淋若涩,是皆火热郁结所致,惟此剂能开郁结,降痰火,并能治之。又其性甘寒,善能治渴,从补药而治虚渴,从凉药而治火渴,从气药而治郁渴,从血药而治烦渴,乃治渴之要药也。
大蒜:性温、味辛平;入脾、胃、肺经。解毒杀虫,消肿止痛,止泻止痢,治肺,驱虫,此外还有温脾暖胃。治痈疽肿毒,白秃癣疮,痢疾泄泻,肺痨顿咳,蛔虫蛲虫,饮食积滞,脘腹冷痛,水肿胀满,行气消积,杀虫解毒。用于感冒、菌痢、阿米巴痢疾、肠炎、饮食积滞、痈肿疮疡。强力杀菌:大蒜中含硫化合物具有奇强的抗菌消炎作用,对多种球菌、杆菌、真菌和病毒等均有抑制和杀灭作用,是目前发现的天然植物中抗菌作用最强的一种。治疗肿瘤和癌症:大蒜中的锗和硒等元素可抑制肿瘤细胞和癌细胞的生长,实验发现,癌症发生率最低的人群就是血液中含硒量最高的人群。美国国家癌症组织认为,全世界最具抗癌潜力的植物中,位居榜首的是大蒜。排毒清肠,预防肠胃疾病:大蒜可有效抑制和杀死引起肠胃疾病的幽门螺杆菌等细菌病毒,清除肠胃有毒物质,刺激胃肠粘膜,促进食欲,加速消化。降低血糖,预防糖尿病:大蒜可促进胰岛素的分泌,增加组织细胞对葡萄糖的吸收,提高人体葡萄糖耐量,迅速降低体内血糖水平,并可杀死因感染诱发糖尿病的各种病菌,从而有效预防和治疗糖尿病。治疗心脑血管疾病:大蒜可防止心脑血管中的脂肪沉积,诱导组织内部脂肪代谢,显著增加纤维蛋白溶解活性,降低胆固醇,抑制血小板的聚集,降低血浆浓度,增加微动脉的扩张度,促使血管舒张,调节血压,增加血管的通透性,从而抑制血栓的形成和预防动脉硬化。每天吃2~3瓣大蒜,是降压的最好最简易的办法,大蒜可帮助保持体内一种酶的适当数量而避免出现高血压。
马铃薯:味甘;性平。功能主治:和胃健中;解毒消肿。主胃痛;痄肋;痈肿;湿疹;烫伤。
蚂蚁:味咸;酸;性平。归肝;肾经。功能主治:补肾益精;通经活络;解毒消肿。主肾虚头昏耳鸣;失眠多梦;阳痿遗精;风湿痹痛;中风偏瘫6;手足麻木;红斑性狼疮;硬皮病;皮肌炎;痈肿疔疮;毒蛇咬伤。
达仑木:酸;辛;微苦;微温。功能主治:祛风消肿;散瘀止痛。主跌打损伤;风湿骨痛;胃肠绞痛;蜂窝组织炎;脓肿;口腔炎。
大黄:主治实热便秘;热结胸痞;湿热泻痢;黄疸;淋病;水肿腹满;小便不利;目赤;咽喉肿痛;口舌生疮;胃热呕吐;吐血;咯血;衄血;便血;尿血;蓄血;经闭;产后瘀滞腹痛;症瘕积聚;跌打损伤;热毒痈疡;丹毒;烫伤。
糯米:甘,温。主治补中益气,治消渴溲多,自汗,便泄。用于脾虚食少,乏力便溏,妇人脏躁。免疫抑制作用:大枣的醇提物以每天100mg给大鼠灌胃,显示大枣与硫唑嘌呤具有同样的免疫抑制作用,对特异反应性疾病能抑制抗体的产生。大枣醇提物可能对大鼠反应性抗体有抑制作用,而对非反应性抗体不产生抑制作用。大枣中的黄酮双葡萄糖苷A,药理实验证明有镇静、催眠和降压作用,大枣有增加白血球内cAMP的作用。大枣煎剂能降低CCl4对肝脏的损伤。
滑石:甘、淡,寒。归膀胱、肺、胃经。功能主治:利尿通淋,清热解暑,祛湿敛疮。用于热淋,石淋,尿热涩痛,暑湿烦渴,湿热水泻;外治湿疹,湿疮,痱子。
射干:味苦,性寒,归肺、肝经,具有清热解毒,清痰利咽的作用,用于热毒痰火郁结,咽喉肿痛,痰涎壅盛,咳嗽气喘等证,射干常用来治疗呼吸道的疾病,在抗病毒性呼吸道疾病的复方中常作为主药。射干中的异黄酮类和三萜类物质为其主要的抗病毒成分。目前射干中异黄酮类物质已报道的有30多种化合物。异黄酮类成分具有抗炎、清除自由基、抗菌、抗病毒和抗氧化等作用所致的肺炎的发生发展,减轻炎症,并且对疱疹病毒Ⅰ所致细胞病变有延迟作用。据相关报道,射干中的三萜皂甙类成分具有增强机体细胞免疫、促进抗体和补体的生成,调节细胞因子等作用。
山豆根:苦,寒;有毒。归肺、胃经。功能主治:清热解毒,消肿利咽。用于火毒蕴结,咽喉肿痛,齿龈肿痛。
大青叶:主要用于热毒发斑、丹毒、咽喉肿痛、口舌生疮、疮痈肿毒等症。近年来此药在临床上广泛应用,除可用治上述诸症外,又可用于痰热郁肺、咯痰黄稠;尤常用于流行性乙性脑炎,既可单味应用于预防,又可配合柴胡、银花、连翘、板蓝根、玄参、生地黄等,能清解气分、营分的热毒,可用治各种乙脑,而以偏热型较为合适。《纲目》:“主热毒痢,黄疸,喉痹,丹毒。”“蓝叶汁,解斑蝥、芫青、樗鸡,朱砂、砒石毒。”《本草正》:“治瘟疫热毒发狂,风热斑疹,痈疡肿痛,除烦渴,止鼻衄、吐血,杀疳蚀、金疮箭毒。凡以热兼毒者,皆宜蓝叶捣汁用之。”
葶苈子:辛;苦;寒。归肺经;心经;肝经;胃经;膀胱经。功能:泻肺降气;祛痰平喘;利水消肿;泄逐邪。主治:痰涎壅肺之喘咳痰多;肺痈;水肿;胸腹积水;小便不利;慢性肺源性心脏病;心力衰竭之喘肿;瘰疬结核。
丹皮:《本草纲目》:“滋阴降火,解斑毒,利咽喉,通小便血滞。后人乃专以黄蘖治相火,不知丹皮之功更胜也。赤花者利,白花者补,人亦罕悟,宜分别之。”现代研究,所含牡丹酚及其以外的糖苷类成分均有抗炎作用;牡丹皮的甲醇提取物有抑制血小板作用;牡丹酚有镇静、降温、解热、镇痛、解痉等中枢抑制作用及抗动脉粥样硬化、利尿、抗溃疡等作用。
生地黄:具有抗炎、抗过敏作用。地黄煎剂灌胃对大白鼠甲醛性关节炎和蛋清性关节炎有明显的对抗作用,并能抑制松节油皮下注射引起的肉芽肿和组胺引起的毛细血管通透性的增加.地黄水提取液对组胺引起的血管通透性增加和醋酸引起的小鼠腹膜炎有明显抑制作用,对蛋清所致急性炎症也有抗炎作用,而地黄的醇及醚提取液则无抗炎作用。具有抗真菌作用,地黄水浸剂对须疮癣菌、石膏样小芽胞癣菌、羊毛状小芽胞癣菌及奥杜盎小芽胞癣菌等多种真菌的生长有抑制作用。具有对抗地塞米松对垂体-肾上腺皮质系统的抑制作用,并能促进肾上腺皮质激素的合成。
玄参:具有抗菌作用。在试管内,玄参对须疮癣菌、絮状表皮癣菌及羊毛状小芽胞癣菌有抑制作用。玄参水浸剂(1:3)在试管内对奥杜盎小芽胞癣菌也有抑制作用。实验表明:玄参叶的抑菌效力比根强,其中对金黄色葡萄球菌尤为明显。
甘草:性平,味甘,归十二经。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性有解毒、祛痰、止痛、解痉以至抗癌等药理作用,甘草具有降血脂、抗氧化的作用。
杏仁:苦,微温。止咳平喘,润肠通便。镇咳、平喘作用,用于咳嗽气喘。本品主入肺经。味苦能降,且兼疏利开通之性,降肺气之中兼有宣肺之功而达止咳平喘,为治咳喘之要药。随证配伍可用于多种咳喘病证。如风寒咳喘,配伍麻黄、甘草,以散风寒,宣肺平喘,即三拗汤。风热咳嗽,配伍桑叶,菊花,以散风热,宣肺止咳,如桑菊饮。燥热咳嗽,配伍桑叶、贝母、沙参,以清肺润燥止咳,如桑杏汤。肺热咳喘,配伍石膏等以清肺泄热,宣肺平喘,如麻杏石甘汤。对消化系统的作用,杏仁味苦下气,且富含脂肪油。脂肪油能提高肠内容物对黏膜的润滑作用,故杏仁有润肠通便之功能。抗炎、镇痛作用,苦杏仁苷分解产生的苯甲醛静安息香缩合酶作用生成安息香。安息香具有镇痛作用,因此国内有人用苦杏仁治疗晚期肝癌可解除病人的痛苦,有的甚至不需服用止痛药。抗肿瘤作用,有关杏仁抗肿瘤机理的研究主要有以下几方面:①一部分学者认为癌细胞中含有大量β-葡萄糖苷酶,该酶能水解苦杏仁苷产生氢氰酸(HCN)、苯甲醛和葡萄糖。由于癌细胞缺少硫腈生成酶,该酶具有对HCN的解毒作用,使HCN变成无毒的硫腈化物,而正常细胞缺少β-葡萄糖苷酶而含有大量的硫腈生成酶。依据该理论,苦杏仁苷应该能够选择性杀死癌细胞,而对正常细胞几乎无害。②苦杏仁苷能帮助体内胰蛋白酶消化癌细胞的透明样黏蛋白膜,使体内白细胞更易接近癌细胞,并吞噬癌细胞。③有人发现苦杏仁苷类似NaSCN和NaOCN能够影响胸腺嘧啶核苷进入肝瘤细胞DNA和肿瘤细胞对磷酸盐及氨基酸的吸收。降血糖作用,苦杏仁苷具有治疗因抗肿瘤药阿脲引起的糖尿病的作用。采用阿脲诱发小鼠高血糖法证明,预先腹腔注射3g/kg苦杏仁苷48h后测血糖,结果表明苦杏仁苷可特异性地抑制阿脲所致的血糖升高,作用强度与血液中苦杏仁苷的浓度有关。降血脂作用,临床报道,大杏仁可以明显降低高血脂患者的血脂水平,Spiller(1990年)认为杏仁中的单不饱和脂肪酸有助于降低患者轻度升高的血脂,且无需严格限制饮食。美容作用,根据肺合皮毛理论,在临床上对某些皮肤疾病可从宣肺法论治,配伍食用杏仁,常获捷效。现代研究证明,苦杏仁中所含的脂肪油可使皮肤角质层软化,从而达到美容的效果。用于肠燥便秘,本品含有油脂而质润,味苦而下气,故能润肠通便。常配伍柏子仁、郁李仁等同用,如《世医得效方》之五仁丸。
地丁:苦,寒.入心、肝经。功能主治:清热利湿,解毒消肿。治疔疮,痈肿,瘰疬,黄疸,痢疾,腹泻,目赤,喉痹,毒蛇咬伤。
柳絮:苦;性凉。功能主治:凉血止血;解毒消痈。主吐血;创伤出血;痈疽;恶疮。
浮萍:辛,寒。归肺经。功能主治:宣散风热,透疹,利尿。用于麻疹不透,风疹瘙痒,水肿尿少。
白矾:性味酸涩,寒,有毒。故有抗菌作用、收敛作用等,可用做中药。明矾又名白矾,是明矾石的提炼品。明矾性寒味酸涩,具有较强的收敛作用,中医认为明矾具有解毒杀虫,燥湿止痒,止血止泻,清热消痰的功效。近年来的研究证实,明矾还具有抗菌,抗阴道滴虫等作用。抗菌作用 明矾对多种革兰阴性、阳性球菌和杆菌都有抑制作用;对常见化脓菌有较强抑菌作用.实验表明:明矾对金黄色葡萄球菌、变形杆菌有抑制作用(试管法).对大肠杆菌、绿脓杆菌、炭疽杆菌、弗氏和志贺痢疾杆菌、伤寒杆菌和副伤寒甲杆菌、变形杆菌及葡萄球菌等有抑制作用(纸碟、平板法);对绿色链球菌、溶血性链球菌、肺炎球菌、白喉杆菌作用最强,对牛型布氏杆菌、百日咳杆菌、脑膜炎球菌作用次之,对流感杆菌无作用(纸片法).高浓度明矾液对人型(H37RV)及牛型结核杆菌也有抑制作用.临床上用0.75%枯矾混悬液对控制烧伤创面的绿脓杆菌感染有效。
蒲公英:具有抗病原微生物的作用,蒲公英注射液在试管内对金黄色葡萄球菌耐药菌株、溶血性链球菌有较强的杀菌作用,对肺炎双球菌、脑膜炎球菌、白喉杆菌、绿脓杆菌、变形杆菌、痢疾杆菌、伤寒杆菌等及卡他球菌亦有一定的杀菌作用。蒲公英提取液(1:400)在试管内能抑制结核菌。蒲公英水煎剂(1:80)能延缓ECHO11病毒细胞病变。蒲公英醇提取物31mg/kg能杀死钩端螺旋体。水浸剂对多种皮肤真菌有抑制作用。煎剂给大鼠口服,吸收良好,尿中能保持一定的抗菌作用。还具有保肝、利胆的作用,用蒲公英煎剂灌胃或用蒲公英注射液注射,对四氯化碳引起的谷丙转氨酶升高有明显抑制作用;能显著缓解四氯化碳性肝损伤引起的组织学改变。有报道指出,蒲公英在动物身上有利胆作用。蒲公英液灌胃能使胆囊收缩,奥狄括约肌松弛,有利于胆汁排入肠中。临床上对慢性胆囊痉挛及结石症有效。还具有免疫功能,蒲公英煎剂在体外能显著提高外周血淋巴细胞母细胞转化率,蒲公英多糖能显著增强艾氏癌及MM46肿瘤细胞抗原所致小鼠脚垫迟发型超敏反应强度,并有给药时间越往后越有效的特点,即于抗原刺激后的第11~20日给药或2~20隔日给药有明显作用。蒲公英多糖腹腔注射能显著增强小鼠抗体依赖性巨噬细胞的细胞毒作用。
本发明的药物还包括:陈皮、地沙、丁香和山楂。
陈皮:性温,味辛、苦;归脾、肺经,用于胸腹胀满等症。橘皮辛散通温,气味芳香,长于理气,能入脾肺,故既能行散肺气壅遏,又能行气宽中,用于肺气拥滞、胸膈痞满及脾胃气滞、脘腹胀满等症,用于湿阻中焦、脘腹痞胀、便溏泄泻,以及痰多咳嗽等症。橘皮苦温燥湿而能健脾行气,故常用于湿阻中焦、脘腹胀闷、便溏苔腻等症,可配伍苍术、厚朴同用。又善于燥湿化痰,为治湿痰壅肺、痰多咳嗽的常用要药,用于脾虚饮食减少、消化不良,以及恶心呕吐等症。本品燥湿而能健脾开胃,适用于脾胃虚弱、饮食减少、消化不良、大便泄泻等症,常与人参、白术、茯苓等配合应用。因其既能健脾,又能理气,故往往用作补气药之佐使,可使补而不滞,有防止壅遏作胀作用,此外,橘皮又能和中,可治胃失和降、恶心呕吐。
地沙:性平,味甘。功能主治:健脾,润肺。
丁香:温中、暖肾、降逆。主治:治呃逆、呕吐、反胃、痢疾、心腹冷痛、痃癖、疝气、癣症。性味归经:辛,温。《开宝本草》:“味辛,温,无毒。”入胃、脾、肾经。《日华子本草》:治口气,反胃,疗肾气,奔豚气,阴痛,壮阳,暖腰膝,杀酒毒,消痃癖,除冷劳。
山楂:切片晒干,置锅内用武大炒至外面焦褐色、内部黄褐色为度、喷洒清水,取出晒干,即为焦山楂。具有开胃消食、化滞消积、活血散瘀、化痰行气的功效,性味归经,酸、甘,性微温。主要成分含绿原酸、咖啡酸、山楂酸、齐菊果酸、槲皮素、熊果酸、齐墩果酸、金丝桃甙、表儿茶精等。口服山楂能增加消化酶,促进脂肪的分解和消化,对因吃肉类或油腻过多所致脘腹胀满、嗳气、不思饮食、腹痛、腹泻者,疗效尤佳。此外,现代药物试验表明,山楂有缓慢而持久的降低血压的功效,还可降低胆固醇和甘油三酯,防止动脉粥样硬化,而且还可舒张冠状动脉,增加心肌收缩力,对抗心律失常。因此,有利于治疗高血压、高血脂、动脉硬化及冠心病。
实施例1药物1
本发明实施例提供了一种用于治疗猪丹毒的药物,有以下重量分数的原料药材组成:金银花15重量份、麻腐23重量份、南酸枣18重量份、天花粉15重量份、大蒜15重量份、马铃薯13重量份、蚂蚁17重量份、达仑木21重量份、大黄13重量份、糯米13重量份、滑石14重量份、射干15重量份、山豆根12重量份、大青叶15重量份、葶苈子13重量份、丹皮16重量份、生地黄15重量份、玄参16重量份、甘草17重量份、杏仁18重量份、地丁15重量份、柳絮15重量份、浮萍14重量份、白矾14重量份和蒲公英15重量份。
本发明实施例还提供了一种用于治疗猪丹毒的药物的制备方法,包括以下步骤:
第一步,将所有原料药按比例混合,粉碎成粉末,装入多功能提取罐中,加入相对于混合物质量5倍的醇浓度为80%的乙醇,加热回流3小时提取,获得提取液,加热回流过程中的蒸汽压力为0.4MPa,将提取液过滤获得第一过滤液和滤渣;
第二步,将第一步获得的滤渣加入相对于第一步混合物质量3倍的醇浓度为80%的乙醇,加热回流1.5小时提取,获得提取液,加热回流过程中的蒸汽压力为0.4MPa,将提取液过滤获得第二过滤液;
第三步,将第一过滤液和第二过滤液合并,减压浓缩除去溶剂,获得干膏,将干膏放入喷雾干燥机中干燥,保证进风温度在170℃,出风温度60℃,随后粉碎成400目,获得粉末药物。
实施例2药物2
本发明实施例提供了一种用于治疗猪丹毒的药物,药物由以下原料药材组成:金银花15重量份、麻腐23重量份、南酸枣18重量份、天花粉15重量份、大蒜15重量份、马铃薯13重量份、蚂蚁17重量份、达仑木21重量份、大黄13重量份、糯米13重量份、滑石14重量份、射干15重量份、山豆根12重量份、大青叶15重量份、葶苈子13重量份、丹皮16重量份、生地黄15重量份、玄参16重量份、甘草17重量份、杏仁18重量份、地丁15重量份、柳絮15重量份、浮萍14重量份、白矾14重量份、蒲公英15重量份、陈皮13重量份、地沙15重量份、丁香15重量份和山楂15重量份。
本发明实施例还提供了一种用于治疗猪丹毒的药物的制备方法,包括以下步骤:
第一步,将所有原料药按比例混合,粉碎成粉末,装入多功能提取罐中,加入相对于混合物质量4倍的醇浓度为85%的乙醇,加热回流2小时提取,获得提取液,加热回流过程中的蒸汽压力为0.5MPa,将提取液过滤获得第一过滤液和滤渣;
第二步,将第一步获得的滤渣加入相对于第一步混合物质量2倍的醇浓度为85%的乙醇,加热回流1小时提取,获得提取液,加热回流过程中的蒸汽压力为0.5MPa,将提取液过滤获得第二过滤液;
第三步,将第一过滤液和第二过滤液合并,减压浓缩除去溶剂,获得干膏,将干膏放入喷雾干燥机中干燥,保证进风温度在180℃,出风温度70℃,随后粉碎成300目,获得粉末药物。
毒性试验
1、急性毒性试验
按照急性毒性试验要求进行预试,发现受试药物无法测出LD50。故进行一日内最大给药量试验。取上述小鼠40只,禁食不禁水12小时后,按体重随机分为给药组和水对照组,每组20只,给药组给含实施例1制备的药物1的生药量2.4g/ml浓度的药液0.4ml/10g,灌胃一天2次,使一日内给药剂量达合生药量192.0g/kg,水对照组给同等体积的水。各组动物给药后,每盒5只,正常饲养,密切观察,均连续观察七天,记录可能出现的毒性反应和死亡情况,给药后,小鼠外观毛色光亮,行为活动正常,无异常病理性神经反射出现,七天中进食良好,末见其它异常表现,体重变化与水对照组相比无明显差异且无一动物死亡,肉眼观察心、肝、脾、肺、肾等主要脏器,无明显的出血、组织变性、坏死等大体病理改变。使用本发明实施例2的药物2对小鼠进行上述试验,结果如实施例1药物1的测试结果相同。
长期毒性试验
本发明实施例1的药物水溶液对小鼠按10.78、20.35和33.48g生药/kg连续灌服16周(1.0ml/100g体重,每天2次)及停药4周后,结果表明:本发明药物对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药16周及停药4周后,小鼠各脏器均无明显改变。说明本发明药物对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。使用本发明实施例2的药物2对小鼠进行上述试验,结果如实施例1药物1的测试结果相同。
临床试验
1.1供试材料
1.1.1供试动物
山东省潍坊市某养猪场中,随机挑选3月龄健康仔猪150头。
供试菌株
山东省某猪个体养殖户,发现仔猪死亡现象,其他仔猪精神不振,高烧,不食,呕吐,结膜充血,粪便干硬,附有粘液,腋下、股内、腹内有不规则鲜红色斑块,指压褪色后融合一起。将死亡仔猪解剖后,发现胃底及幽门部薄膜发生弥漫性出血,小点出血;整个肠道都有不同程度的卡他性或出血性炎症,脾肿大,呈典型败血脾。将死亡猪的肝脏等病料无菌取样,接种鲜血琼脂培养基,于37℃恒温湿培养24h,观察菌落形态,然后挑选可疑菌落进行纯培养。镜检可见革兰氏阳性细小杆菌,纤细杆状者居多,易形成长丝状,两端钝圆,美兰染色呈着色深的球杆状,间有长而弯曲的丝状菌体。将分离到的丹毒杆菌攻毒两头哺乳仔猪,于24小时后发现猪丹毒症状,确定死亡仔猪为猪丹毒致死。将分离的菌株作为供试菌株。
供试药品
实施例1的药物1;实施例2的药物2;传统药物:阿莫西林+清开灵注射液。
试验方法
1.2.1接种试验
将培养的丹毒菌株分别静脉注射134头供试仔猪,感染一天后均出现猪丹毒症状,选择其中120头患病仔猪作为实验猪。
实验分组
将120头患病仔猪随机分成三组,每组40头,即实施例组1、实施例组2和对照组。
试验方法
感染后出现猪丹毒病的仔猪分别采用不同的药物治疗,其中,实施例组1使用本发明实施例1的药物1进行治疗,将药物1:4的重量百分比溶在水中灌服,每天三次,每次灌服5g药物1,或将药物1按照8:100的重量百分比混入饲料中,按照正常饲喂方式喂养,连续使用4天;实施例组2使用本发明实施例2的药物2治疗,使用方法如药物1的方法相同;对照组使用阿莫西林2克/50公斤体重+清开灵注射液20毫升/50公斤体重,每天一次,连用4天。
观察记录
感染后观察各组仔猪的临床症状和病理变化,记录感染后死亡数和治疗结束后的治疗效果。
结果
2.1疗效标准
治愈:患病仔猪精神、食欲、体温、排便均恢复正常,腋下、股内、腹内的鲜红色斑块均消失;
有效:患病仔猪精神、食欲、体温、排便均恢复正常,腋下、股内、腹内的红色斑块明显好转;
无效:患病仔猪症状未消失或病情恶化甚至死亡。
其中,有效率为治愈和有效的百分比之和。
观察结果如表1所示。
表1治疗结果对照表
组别死亡数(只)治愈(只)有效(只)无效(只)有效率(%)
实施例组11297490.0%
实施例组21307392.5%
对照组32012880.0%
从表1的数据可知:与对照组相比,本发明实施例1和实施例2的药物对猪丹毒的治疗具有疗效显著,副作用低,治疗有效率高的优点;在随后的长期观察中发现,实施例组1和实施例组2治愈的仔猪再次发病率明显低于对照组的仔猪。
感染后症状与剖检结果
感染后,患病仔猪的症状为:精神不振,高烧,不食,呕吐,结膜充血,粪便干硬,附有粘液,腋下、股内、腹内有不规则鲜红色斑块,指压褪色后融合一起。将死亡仔猪解剖后,发现胃底及幽门部薄膜发生弥漫性出血,小点出血;整个肠道都有不同程度的卡他性或出血性炎症,脾肿大,呈典型败血脾。
具体病例
病例1
孙某家养的两头猪发现精神不振,不食,一天后出现高烧、呕吐和结膜充血的现象,两天后出现腋下和腹内有鲜红色斑块,指压褪色后融合一起,确诊为猪丹毒,使用本发明实施例1的药物治疗,将药物1按照饲料8%的重量百分比混入饲料中,按照常规喂养方式喂养,连续使用4天,两头猪均恢复正常。
病例2
某养猪场的51头哺乳仔猪,三头仔猪出现死亡现象,死亡前腋下、股内、腹内有不规则鲜红色斑块,指压褪色后融合一起,将死亡仔猪解剖后,发现胃底及幽门部薄膜发生弥漫性出血,小点出血;整个肠道都有不同程度的卡他性或出血性炎症,脾肿大,呈典型败血脾,其他仔猪均有食欲不振,精神低迷,腋下出现鲜红色斑块的症状,确诊为猪丹毒,使用本发明实施例2的药物2按照1:4的重量份数比溶解在水中灌服,每天三次,每次灌服5g药物2,连续使用3天,38头仔猪均恢复正常,继续治疗2天,48头仔猪均恢复正常。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.用于治疗猪丹毒的药物,其特征在于,所述药物由以下重量份数的原料药制成:金银花10~20重量份、麻腐18~28重量份、南酸枣10~26重量份、天花粉10~20重量份、大蒜10~20重量份、马铃薯10~15重量份、蚂蚁10~20重量份、达仑木10~26重量份、大黄10~20重量份、糯米10~15重量份、滑石10~26重量份、射干10~25重量份、山豆根10~15重量份、大青叶10~20重量份、葶苈子10~20重量份、丹皮10~24重量份、生地黄10~26重量份、玄参10~20重量份、甘草10~24重量份、杏仁10~24重量份、地丁10~20重量份、柳絮10~20重量份、浮萍10~15重量份、白矾10~15重量份和蒲公英10~20重量份。
2.根据权利要求1所述的用于治疗猪丹毒的药物,其特征在于,所述药物由以下重量份数的原料药制成:金银花12~17重量份、麻腐19~25重量份、南酸枣14~22重量份、天花粉13~18重量份、大蒜12~17重量份、马铃薯10~15重量份、蚂蚁15~20重量份、达仑木15~26重量份、大黄10~15重量份、糯米10~15重量份、滑石10~18重量份、射干10~21重量份、山豆根10~15重量份、大青叶10~17重量份、葶苈子10~16重量份、丹皮12~20重量份、生地黄13~18重量份、玄参13~18重量份、甘草13~21重量份、杏仁15~21重量份、地丁12~17重量份、柳絮12~18重量份、浮萍13~15重量份、白矾13~15重量份和蒲公英13~17重量份。
3.根据权利要求1所述的用于治疗猪丹毒的药物,其特征在于,所述药物由以下重量份数的原料药制成:金银花15重量份、麻腐23重量份、南酸枣18重量份、天花粉15重量份、大蒜15重量份、马铃薯13重量份、蚂蚁17重量份、达仑木21重量份、大黄13重量份、糯米13重量份、滑石14重量份、射干15重量份、山豆根12重量份、大青叶15重量份、葶苈子13重量份、丹皮16重量份、生地黄15重量份、玄参16重量份、甘草17重量份、杏仁18重量份、地丁15重量份、柳絮15重量份、浮萍14重量份、白矾14重量份和蒲公英15重量份。
4.用于治疗猪丹毒的药物,其特征在于,所述药物由以下原料药制成:金银花12~17重量份、麻腐19~25重量份、南酸枣14~22重量份、天花粉13~18重量份、大蒜12~17重量份、马铃薯10~15重量份、蚂蚁15~20重量份、达仑木15~26重量份、大黄10~15重量份、糯米10~15重量份、滑石10~18重量份、射干10~21重量份、山豆根10~15重量份、大青叶10~17重量份、葶苈子10~16重量份、丹皮12~20重量份、生地黄13~18重量份、玄参13~18重量份、甘草13~21重量份、杏仁15~21重量份、地丁12~17重量份、柳絮12~18重量份、浮萍13~15重量份、白矾13~15重量份、蒲公英13~17重量份、陈皮10~15重量份、地沙10~20重量份、丁香10~20重量份和山楂10~20重量份。
5.根据权利要求4所述的用于治疗猪丹毒的药物,其特征在于,所述药物由以下原料药制成:金银花15重量份、麻腐23重量份、南酸枣18重量份、天花粉15重量份、大蒜15重量份、马铃薯13重量份、蚂蚁17重量份、达仑木21重量份、大黄13重量份、糯米13重量份、滑石14重量份、射干15重量份、山豆根12重量份、大青叶15重量份、葶苈子13重量份、丹皮16重量份、生地黄15重量份、玄参16重量份、甘草17重量份、杏仁18重量份、地丁15重量份、柳絮15重量份、浮萍14重量份、白矾14重量份、蒲公英15重量份、陈皮13重量份、地沙15重量份、丁香15重量份和山楂15重量份。
6.一种如权利要求1-5任一项所述的用于治疗猪丹毒的药物的制备方法,其特征在于,所述制备方法包括以下步骤:
第一步,将所有原料药按比例混合,粉碎成粉末,装入多功能提取罐中,加入相对于混合物质量3~5倍的醇浓度为80%~90%的乙醇,加热回流1小时~3小时提取,获得提取液,加热回流过程中的蒸汽压力为0.4MPa~0.6MPa,将提取液过滤获得第一过滤液和滤渣;
第二步,将第一步获得的滤渣加入相对于第一步混合物质量1~3倍的醇浓度为80%~90%的乙醇,加热回流0.5小时~1.5小时提取,获得提取液,加热回流过程中的蒸汽压力为0.4MPa~0.6MPa,将提取液过滤获得第二过滤液;
第三步,将第一过滤液和第二过滤液合并,减压浓缩除去溶剂,获得干膏,将干膏放入喷雾干燥机中干燥,保证进风温度在170℃~190℃,出风温度60℃~80℃,随后粉碎成200目~400目,获得粉末药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310744844.2A CN103721103B (zh) | 2013-12-30 | 2013-12-30 | 用于治疗猪丹毒的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310744844.2A CN103721103B (zh) | 2013-12-30 | 2013-12-30 | 用于治疗猪丹毒的药物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103721103A CN103721103A (zh) | 2014-04-16 |
| CN103721103B true CN103721103B (zh) | 2015-12-02 |
Family
ID=50445564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310744844.2A Active CN103721103B (zh) | 2013-12-30 | 2013-12-30 | 用于治疗猪丹毒的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103721103B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105582066A (zh) * | 2014-11-13 | 2016-05-18 | 天津市中敖饲料有限公司 | 治疗猪丹毒的中药煎煮液及其制备方法 |
| CN106266539A (zh) * | 2016-08-26 | 2017-01-04 | 任英明 | 一种治疗仔猪白痢的中兽药 |
| CN106215008A (zh) * | 2016-08-26 | 2016-12-14 | 任英明 | 一种治疗猪肺炎的中兽药 |
| CN106362057A (zh) * | 2016-08-26 | 2017-02-01 | 任英明 | 一种治疗猪疥癣病的中兽药 |
| CN106215009A (zh) * | 2016-08-26 | 2016-12-14 | 任英明 | 一种治疗猪瘟的中兽药 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142824A (zh) * | 2013-04-02 | 2013-06-12 | 河北工程大学 | 一种防治猪丹毒病的药物 |
-
2013
- 2013-12-30 CN CN201310744844.2A patent/CN103721103B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142824A (zh) * | 2013-04-02 | 2013-06-12 | 河北工程大学 | 一种防治猪丹毒病的药物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103721103A (zh) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103689296B (zh) | 妊娠后期和哺乳期的母羊饲料及其制备方法 | |
| CN101804166B (zh) | 一种治疗小儿皮炎湿疹的中药组合物 | |
| CN102940155B (zh) | 一种樱桃谷鸭的雏鸭饲料及其制备方法 | |
| CN104187172B (zh) | 用于治疗乌龟肠胃炎病的功能性饲料及其制备方法 | |
| CN104799115A (zh) | 一种鸡配合饲料及其制备方法 | |
| CN104068279B (zh) | 一种含有中药添加剂的鳗鱼饲料及其制备方法 | |
| CN103721103B (zh) | 用于治疗猪丹毒的药物及其制备方法 | |
| CN102696928B (zh) | 用于治疗猪流感的饲料、中药组合物、制备方法和应用 | |
| CN103041256B (zh) | 一种治疗小儿反复呼吸道感染的中药制剂 | |
| CN102846864B (zh) | 一种防治猪传染性萎缩性鼻炎的中药兽药及其制备方法 | |
| CN104256166A (zh) | 一种用于治疗牛蓝舌病的功能性饲料及其制备方法 | |
| CN103520605B (zh) | 用于治疗柔嫩艾美尔球虫感染的饲料 | |
| CN103041257B (zh) | 治疗小儿发热高烧呼吸道感染的中药制剂 | |
| CN103494927A (zh) | 一种用于治疗鸡呼吸道疾病的中药组合物及其制备方法 | |
| CN103719552B (zh) | 用于防治猪丹毒的饲料及其制备方法 | |
| CN103652490B (zh) | 用于治疗猪蓝耳病的猪饲料及其制备方法 | |
| CN103041255B (zh) | 治疗小儿咽喉肿痛呼吸道感染的中药制剂 | |
| CN103495072A (zh) | 一种治疗支气管扩张病的中药组合物及其制备方法 | |
| CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
| CN105709101A (zh) | 一种治疗睑缘炎的中药制剂及其制备方法 | |
| CN103690771B (zh) | 用于治疗羔羊大肠杆菌病的药物及其制备方法 | |
| CN103041258B (zh) | 治疗小儿呼吸道感染伴纳差不食的中药制剂 | |
| CN106377659A (zh) | 一种用于防治畜禽温热性疾病的中药粉剂及其制备方法 | |
| CN106334155A (zh) | 一种治疗动甲状腺肿大的中药组合物及其制备方法 | |
| CN103948840A (zh) | 一种用于治疗猪异食癖的中药添加剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191106 Address after: 401320 Maliu Yanjiang Development Zone, Banan District, Chongqing Patentee after: Chongqing new hope feed Co., Ltd. Address before: 266061 Shandong city of Qingdao province Chengyang Jihongtan Street Green Industrial Park Patentee before: Shandong New Hope Liuhe Group Co., Ltd. |